Basic fibroblast growth factor (bFGF) inhibits radiation-induced apoptosis, and radioprotects haematopoietic, cartilage growth plate, pulmonary and gastrointestinal tissues. Conversely, chronic overexpression of bFGF may promote fibrosis. We measured the endogenous circulating bFGF in blood of patients undergoing conditioning TBI. Twenty-six patients with haematopoietic malignancies were conditioned with cyclophosphamide/TBI for allogeneic BMT. Daily blood samples were collected each morning prior to, during, and for several days after TBI. bFGF levels in plasma of normal volunteers are 0.8-26 pg/ml. bFGF was below detectability in 22%, 30% and 45% of patients pre-TBI, during TBI or post-TBI respectively. Mean circulating plasma levels of bFGF decreased from a median of 52 pg/ml pre-TBI to 26 pg/ml during TBI, and to 5 pg/ml post-TBI. Among the 26 patients, 13 had more than one non-detectable plasma bFGF level, an additional five had at least one non-detectable level, and only eight patients had detectable levels in all daily samples. Naturally high levels of bFGF were observed in some patients undergoing fractionated TBI. In contrast, as many as 79% of patients had low bFGF levels in one or more samples. The impact of endogenous bFGF on the tolerance of normal tissues to irradiation is unknown, and warrants further study.
Basic fibroblast growth factor (bFGF), also called FGF2, is a member of a family of cytokines that include acidic FGF (FGF1), and keratinocyte growth factor (KGF or FGF7). Basic fibroblast growth factor (bFGF) is among the most powerful angiogenic peptides. It has pleotropic effects when applied to various tissues, [1] [2] [3] [4] [5] [6] [7] including mitogenesis and differentiation of endothelial cells and fibroblasts, stimulation of fibroblasts to produce collagen, and it is an important and early link in the wound healing cytokine cascades. The various FGFs share sequence homology, but appear to bind difCorrespondence: Dr P Okunieff, Dept Radiation Oncology, Strong Memorial Hospital, 601 Elmwood Ave, Box 647, Rochester, NY, 14642, USA Received 28 September 1998; accepted 6 January 1999 ferent receptors with variable affinity and commonly gain extracellular exposure by very different processes. [7] [8] [9] [10] [11] [12] [13] bFGF and other members of the FGF family of proteins have been shown to radioprotect the small bowel epithelium. 14, 15 bFGF has been shown to radioprotect haematopoietic progenitors with particularly beneficial effects on megakaryopoiesis and erythropoiesis, 3 and bFGF also appears to prevent pulmonary and vascular toxicity by reducing apoptosis of endothelium. 16, 17 bFGF has been shown to alleviate bone growth retardation in juvenile mice, even when given a month or more after irradiation. 18 Indeed, most studies to date have shown a radioprotective benefit of bFGF when given either before or after irradiation, with the greatest benefit derived in the preceding 48 h or within the first 24 h following irradiation. Other cytokines are also known to radioprotect a variety of tissues, but most notably bone marrow. Marrow radiation protectors include IL-1, TNF-␥, and several colony-stimulating factors. 19 Among these biological radiation modifiers, only IL-1 radioprotects non-haematopoietic tissues (small bowel), and conversely, TNF isoforms can be powerful radiosensitizers of non-haematological tissue. 20 bFGF is generally considered to be a paracrine and autocrine growth factor. However, bFGF has the potential of acting in an endocrine fashion considering the proteolysis protection afforded by its tight coupling to heparin. Pre-clinical studies confirm the potential endocrine function of bFGF in that systemic administration (i.v. or s.c.) can have multiorgan radioprotective benefit. 18, 21 Conditioning for bone marrow transplantation often includes irradiation. Independent of conditioning regimen, however, the major toxicities of therapy include gastrointestinal damage with associated malnutrition and infection, pulmonary toxicity and associated pneumonitis, and vascular damage and associated veno-occlusive disease. Protection against these non-haematopoietic toxicities along with the myeloprotective effects of bFGF on erythropoietic and megakaryopoietic precursors, leads to the hypothesis that bFGF could prove an effective, naturally produced, modifier of treatment-induced toxicity. We therefore measured the endogenous level of circulating bFGF before, during and after, total body irradiation (TBI) for conditioning of allogeneic bone marrow transplantation.
Materials and methods
Twenty-six patients with haematopoietic malignancies were conditioned with cyclophosphamide/TBI for allogeneic Figure 1 bFGF levels of Cy/TB patients. Mean and median bFGF concentrations in patients undergoing TBI for allogeneic bone marrow transplantation is plotted as a function of the day in the conditioning sequence. There was a steady decrease in both mean and median bFGF concentrations during (solid black time period) TBI. bFGF concentrations remained low for several weeks following reinfusion of marrow (not shown). Error bars are one standard error of the mean. *P р 0.05 compared to pre-TBI. bone marrow transplantation. Most patients had active chronic myelogenous leukaemia, all were adults, and all had received previous chemotherapy. Chemotherapy, usually hydroxyurea, was discontinued for several weeks prior to conditioning in most patients. Radiation was delivered at 1.7 Gy per fraction for a total of 13.6 Gy over 4 days in 8 fractions. Daily blood samples were collected early each morning using EDTA anticoagulation prior to, during, and for several days following TBI but preceding the allogeneic marrow reinfusion. The time periods before and after completion of TBI were chosen based on pre-clinical data demonstrating a radioprotective effect of bFGF during those periods. 19, [21] [22] [23] [24] [25] [26] Daily blood samples collected during the week following the reinfusion of marrow suggest that marrow reinfusion has no significant effect on plasma bFGF concentrations. After collection in EDTA, plasma was briefly stored on ice, centrifuged at 3000 g for 30 min and aliquoted for later analysis. Specimens were stored at −70°C. Control studies indicate that loss of bFGF activity, if any, was minimal during the storage period. The stability (Ϯ10%) of plasma bFGF at −70°C has been confirmed by other investigators. [27] [28] [29] Plasma bFGF concentrations were measured in batches using ELISA kits and protocols specified by the manufacturer (R&D Systems, Minneapolis, MN, USA). The ELISA kit has a detection limit of Ϸ1 pg/ml.
Comparisons between means was done using Student's t-test. Since data are not Gaussian in distribution, means and medians are reported along with cumulative distributions as appropriate.
Results
The range of circulating bFGF in normal volunteers was 0.8-26 pg/ml. Mean pre-TBI bFGF in patients studied was 79 Ϯ 102 (s.d.) pg/ml (median 52 pg/ml) during the 72 h before the start of TBI. A total of 69 daily specimens (two or three per patient) were collected during the pre-TBI period, and 15 measurements (22%) were below detectability. During TBI, mean circulating plasma levels of bFGF decreased to 54 Ϯ 92 (s.d.) pg/ml (P = 0.09 compared to pre-TBI), with a median level of 26 pg/ml. Of a total of 101 daily blood assays (three or four per patient), bFGF was undetectable in 30 measurements (30%). In the 48 h period after completion of TBI (post-TBI), 49 bFGF measurements were made (one or two for each patient). The mean bFGF level decreased significantly compared to pre-TBI (39 Ϯ 72 pg/ml; p = 0.02). Likewise, the median bFGF level also decreased dramatically to 5 pg/ml, and the frequency of undetectable bFGF levels increased to 22 of the 49 measurements (45%). Among the 26 patients, 13 (50%) had more than one non-detectable plasma bFGF measurement, an additional five (19%) had one non-detectable level. Eight patients (31%) had detectable levels in all measurements. Figure 1 shows the mean and median bFGF levels as a function of time during the conditioning regimen for transplant. Median levels were always less than the mean due to occasional high endogenous levels in individual patients. Compared to the 3 days prior to conditioning, mean levels were significantly reduced at the end of TBI. Figure 2 shows the percent of patients on any given day with a bFGF level in the lowest quartile of the normal range (р5 pg/ml). The percent of patients with low bFGF increased during the conditioning regimen. Figure 3 shows the cumulative frequency of patients with a low bFGF. Ultimately, 79% of patients had at least 1 day during which their bFGF level was р5 pg/ml.
Four patients (15%) had more than one bFGF concentration over 100 pg/ml during TBI, and an additional three patients (12%) had one bFGF concentration over 100 pg/ml during TBI. In total, 12 patients (46%) had a bFGF over 100 pg/ml at some time during the 9 day study period, but during irradiation only two to five patients (8-19%) had these high levels on any given day (Figure 4 ).
Discussion
Patients undergoing allogeneic bone marrow transplantation for leukemia frequently had initial bFGF concentrations greater than 100 pg/ml. This level is four-fold higher than the highest value reported for normal volunteers (0.8-26 pg/ml). The elevation of bFGF may relate to production by the leukaemia itself, 30 or more likely, is a normal tissue response to the stress of the disease or its therapy. 19 Not all patients had initial elevation of bFGF. Those patients with elevated bFGF typically had high levels of the growth factor for several days, with a slow decline during the period of TBI. By the end of TBI, most patients had levels of bFGF at the limits of detectability or in the lowest quartile of normal range (р5 pg/ml). In total, 79% of patients had at least one bFGF level in the р5 pg/ml range, and the same patients also had at least 1 day with bFGF levels below detectability.
Pre-clinical studies demonstrate that FGFs given in almost any schedule beginning 48 h before irradiation to 24 h after irradiation, can reduce haematopoietic toxicity, 19, [21] [22] [23] [24] [25] [26] small bowel crypt stem cell loss, 14,15 pulmonary radiosensitivity, 16, 17, 31, 32 and bone growth defects after irradiation. 5, 18, 33 Other FGF isoforms can also radioprotect in a variety of circumstances. For example, acidic FGF has shown a spectrum of effects similar to bFGF, although usually with less efficiency, and FGF7 (also known as KGF) appears to protect the small bowel to a greater extent than Cy/TBI with high bFGF levels. Daily and cumulative histograms of the percent of patients with bFGF concentrations greater than 100 pg/ml pre-TBI, during TBI, or post-TBI is plotted as a function of the day in the conditioning sequence. During the conditioning course, there was a steady decrease in the fraction of patients with the highest bFGF concentrations. Pre-TBI, nearly a third of patients had bFGF concentrations у100 pg/ml. In the post-TBI period, only about 10% had these high bFGF levels. In total, almost half of patients had one or more days with a bFGF level over 100 pg/ml. Error bars are predicted standard errors of the mean.
bFGF. Interestingly, some effects of bFGF-induced radioprotection can be seen even if bFGF is given a month or more after irradiation. 18 Not all studies confirm the radioprotective effects of bFGF, 34 and its effects on tumor growth and aggressiveness are also model-dependent. For example, there is multilineage radioprotection of marrow progenitors in C3H mice, primarily protection of erythopoietic and megakaryopoietic lines in Balb/C mice, and little or no marrow protection in C57 mice. 23, 35 In one report, pulmonary death was prevented in C3H/HeJ mice given irradiation to their lungs with esophageal shielding, 16, 17 while in another laboratory that did not shield the mediastinum, no radioprotection against either pulmonary death or respiratory rate alteration was detected in two mouse strains. 34 bFGF given with or without radiation in three C3H murine tumors (RIF-1, SCCVII and KHT) did not reduce radiation response or increase growth rate or metastatic potential.
22,24 KGF, 13 like bFGF in the above experiments, appears to have no effect on tumour growth in vitro or in vivo. In some in vivo experimental models, however, an increase in growth and metastases was observed after high-dose bFGF treatment. 36, 37 In the case of these in vivo studies, the differences in observations probably relate to bFGF dose. The studies featuring tumour progression induced by bFGF required total doses approximately an order of magnitude higher and also required long-term exposure of the tumour to the growth factor. Indeed, the prolonged exposure appears to be required for adverse tumour progression since bFGF injected directly into the tumour (but only on one occasion) has no long-term sequellae. On the other hand, in transfection experiments, wherein tumours are chronically exposed to bFGF, bFGF induces mammary carcinoma xenograft aggressiveness. 37, 38 Likewise, breast cancer patients with chronically elevated circulating bFGF levels appear to be at high risk for metastatic disease. 39 Hence, extremely high local levels of bFGF when present for long periods of time appear to enhance tumour growth and metastatic potential. 40 Low or brief exposures do not appear to have adverse tumor sequellae. In contrast, moderate and brief exposures to bFGF can radioprotect several otherwise radiosensitive normal tissues.
It is unknown whether bFGF radioprotection will be effective against non-haematopoietic toxicity when total body radiation is employed. All studies done to date featuring radioprotection of the small bowel, bone growth plate, or lung have featured partial body irradiation. It is also unknown whether bFGF will be chronically reduced after partial body radiation in the way it appears to be reduced after total body irradiation.
bFGF may not be totally beneficial for non-haematological tissues. A related cytokine, TGF␤, a fibrogenic cytokine that under some circumstances is known to reduce 5 fluorouracil haematopoietic toxicity, can actually induce pulmonary fibrosis in clinical and experimental models. 19 Whether other fibrogenic cytokines like bFGF will have similar effects on inducing fibrosis is unknown. Fibrogenesis would be particularly likely if bFGF is delivered chronically and at a high dose. Hence, chronic high exposure to bFGF should be avoided since both tumour recurrence and side-effect induction could be increased.
The half-life of exogenously administered bFGF is variable between species and individuals. Estimates of bFGF half-life in humans range from a few minutes to hours. 41, 42 In mice the half-life is somewhat shorter. In most strains of mice studied, peak radioprotective effects are seen at aFGF or bFGF doses near 6 g/mouse given as an intravenous bolus. It is, however, impossible to determine what the 'optimal' radioprotective level of any FGF isoform will be in humans. Assuming that signal transduction in man and mouse is similar, then scaling by mass or surface area yields an approximate optimal FGF dose of 0.24 mg/kg or 1.1 mg/m 2 , respectively. Alternatively, if area-under-thecurve (integration of concentration-time plot) is most critical, then the optimal dose might be lower at 80 g/kg or 380 g/m 2 . The various calculations nominally lead to circulating bFGF levels in the range of 10-300 pg/ml. The matter is made more complex considering that heparin protects bFGF from proteolysis and thus prolongs its half-life; but heparin also reduces biological activity of bFGF, perhaps by competitively reducing receptor activation. 13, 41 Due to the difficulty of predicting the 'optimal' bFGF blood levels for radioprotection, we assumed technically undetectable bFGF levels and levels in the lowest quartile of the normal range (р5 pg/ml) to be 'inadequate'. Similarly, we considered it reasonable to estimate that levels four-fold above normal range (у100 pg/ml) were 'therapeutic'. With these definitions, only a quarter of patients ever had therapeutic levels, no patient had a fully therapeutic level for the entire period, and over three-quarters of patients had inadequate levels at some point in their therapy.
The conditioning regimen for bone marrow transplantation has two objectives. The first, easily achieved by moderate doses of TBI, is myelosuppression sufficient to allow engraftment of the allogeneic marrow. The second objective is total or near-total leukaemia sterilization, such that graft-versus-tumour can control the residual leukaemia. The second goal is frequently not obtained, leading to the need to increase dose of conditioning TBI. 43 Although higher doses of TBI do improve outcome, these doses have associated non-haematologic toxicities. The subset of patients that are the most sensitive to dose-limiting toxicity will in general dictate the dose used for the whole population. 44, 45 Methods that raise the tolerance of sensitive individuals can allow for dose escalation. This approach to escalation of chemotherapy using GM-CSF is standard practice, and realistically might apply to radiation dose escalation using radiation modifiers such as bFGF or KGF.
The presented data provide evidence that about half of the patients undergoing allogeneic bone marrow transplant for leukaemia have levels of bFGF considerably above normal at some time during their conditioning. During the conditioning TBI regimen, all patients experience a reduction in their bFGF levels, and the median bFGF levels fall below the usual normal range in plasma by the completion of conditioning. If bFGF acts as an endogenous radiation protector of otherwise dose limiting normal tissues including lung and small bowel, and if levels of bFGF below 5 pg/ml are indicative of subtherapeutic levels of this cytokine, then as many as 79% of patients had insufficient levels of bFGF on one or more days during their conditioning regimen. The data suggest that FGFs may have a role to play in alleviating treatment-induced toxicities among patients undergoing bone marrow transplantation. Future studies on a larger cohort are in progress to examine for correlation between clinical outcome and circulating bFGF.
